Literature DB >> 18560764

Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis.

Giovanni Di Maira1, Francesca Brustolon, Kendra Tosoni, Sara Belli, Stefanie D Krämer, Lorenzo A Pinna, Maria Ruzzene.   

Abstract

CK2 is a pleiotropic protein kinase, which phosphorylates many substrates and has a global role in promoting cell survival and preventing apoptosis. In this study, we investigated its involvement in the phenomenon of the drug resistance, by which tumor cells frequently become unresponsive to chemical apoptosis. By comparing the expression of CK2 subunits in four different pairs of sensitive (S) and resistant (R) cancer cell lines, we found that in three cases the resistant phenotype is accompanied by the overexpression of the CK2 catalytic alpha subunit, either alone or in combination with the regulatory beta subunit. The degree of CK2 expression correlates with the CK2 catalytic activity, when measured toward endogenous protein substrates. All the tested R cell lines, including the one with no CK2 overexpression, can be induced to undergo death by treatment with CK2 inhibitors. We therefore conclude that, although CK2 overexpression is not an absolute requirement for the resistant phenotype, its activity is essential for cell survival and contributes to a high degree of resistance. We also found that CK2 inhibition increases the accumulation of cytotoxic drugs inside the R cells, presumably by impairing the functionality of the extrusion pump P-gp. We therefore propose that CK2 should be considered a target to counteract the pharmaco-resistant phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18560764     DOI: 10.1007/s11010-008-9813-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  20 in total

Review 1.  Multidrug resistance: molecular mechanisms and clinical relevance.

Authors:  V Ling
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

Review 2.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.

Authors:  David W Litchfield
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

3.  Protein kinase CK2: a new view of an old molecular complex.

Authors:  Odile Filhol; Jean-Louis Martiel; Claude Cochet
Journal:  EMBO Rep       Date:  2004-04       Impact factor: 8.807

Review 4.  Casein kinase 2: an 'eminence grise' in cellular regulation?

Authors:  L A Pinna
Journal:  Biochim Biophys Acta       Date:  1990-09-24

Review 5.  Protein kinase CK2: a challenge to canons.

Authors:  Lorenzo A Pinna
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

6.  Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.

Authors:  G Di Maira; F Brustolon; J Bertacchini; K Tosoni; S Marmiroli; L A Pinna; M Ruzzene
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

Review 7.  Multidrug resistant proteins.

Authors:  P Borst
Journal:  Semin Cancer Biol       Date:  1997-06       Impact factor: 15.707

8.  Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2').

Authors:  S Sarno; H Reddy; F Meggio; M Ruzzene; S P Davies; A Donella-Deana; D Shugar; L A Pinna
Journal:  FEBS Lett       Date:  2001-05-04       Impact factor: 4.124

Review 9.  A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.

Authors:  M Sawicka; M Kalinowska; J Skierski; W Lewandowski
Journal:  J Pharm Pharmacol       Date:  2004-09       Impact factor: 3.765

10.  2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.

Authors:  Mario A Pagano; Flavio Meggio; Maria Ruzzene; Mariola Andrzejewska; Zygmunt Kazimierczuk; Lorenzo A Pinna
Journal:  Biochem Biophys Res Commun       Date:  2004-09-03       Impact factor: 3.575

View more
  6 in total

1.  Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Authors:  Christian Borgo; Luca Cesaro; Valentina Salizzato; Maria Ruzzene; Maria Lina Massimino; Lorenzo A Pinna; Arianna Donella-Deana
Journal:  Mol Oncol       Date:  2013-08-22       Impact factor: 6.603

2.  Protein kinase CK2 accumulation in "oncophilic" cells: causes and effects.

Authors:  Maria Ruzzene; Kendra Tosoni; Sofia Zanin; Luca Cesaro; Lorenzo A Pinna
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

Review 3.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

4.  Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.

Authors:  Sofia Zanin; Christian Borgo; Cristina Girardi; Sean E O'Brien; Yoshihiko Miyata; Lorenzo A Pinna; Arianna Donella-Deana; Maria Ruzzene
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

5.  Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.

Authors:  Valentina Salizzato; Christian Borgo; Luca Cesaro; Lorenzo A Pinna; Arianna Donella-Deana
Journal:  Oncotarget       Date:  2016-04-05

6.  Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance.

Authors:  Amin Emad; Junmei Cairns; Krishna R Kalari; Liewei Wang; Saurabh Sinha
Journal:  Genome Biol       Date:  2017-08-11       Impact factor: 13.583

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.